Back grey_arrow_rt.gif
Merck's Zostavax Shingles Vaccine Approved
  May 26, 2006-
Merck's Zostavax clears FDA May 26 as the first vaccine approved for the prevention of shingles.
The agency approved Zostavax for prevention of herpes zoster virus in patients ages 60 years and older.
FDA's decision is in line with a December recommendation from its Vaccines & Related Biological Products Advisory Committee, which contended that not enough evidence is available to support approval for immunization of patients ages 50-59.
Approval of Zostavax includes a stipulation for a post-marketing study of safety in patients over 60.
  icon paper stack View Older Articles   Back to Top